AAPL   381.14 (-0.42%)
MSFT   212.65 (-0.78%)
FB   241.90 (-1.06%)
GOOGL   1,519.26 (+0.04%)
AMZN   3,179.87 (-0.09%)
NVDA   420.19 (-0.04%)
CGC   16.86 (+5.24%)
MU   50.07 (+0.18%)
AMD   56.07 (-2.10%)
T   29.88 (+1.15%)
F   5.98 (+2.22%)
GILD   76.14 (+1.91%)
DIS   119.04 (+1.90%)
BAC   23.37 (+2.64%)
NFLX   541.41 (+6.63%)
BA   176.35 (+1.77%)
AAPL   381.14 (-0.42%)
MSFT   212.65 (-0.78%)
FB   241.90 (-1.06%)
GOOGL   1,519.26 (+0.04%)
AMZN   3,179.87 (-0.09%)
NVDA   420.19 (-0.04%)
CGC   16.86 (+5.24%)
MU   50.07 (+0.18%)
AMD   56.07 (-2.10%)
T   29.88 (+1.15%)
F   5.98 (+2.22%)
GILD   76.14 (+1.91%)
DIS   119.04 (+1.90%)
BAC   23.37 (+2.64%)
NFLX   541.41 (+6.63%)
BA   176.35 (+1.77%)
AAPL   381.14 (-0.42%)
MSFT   212.65 (-0.78%)
FB   241.90 (-1.06%)
GOOGL   1,519.26 (+0.04%)
AMZN   3,179.87 (-0.09%)
NVDA   420.19 (-0.04%)
CGC   16.86 (+5.24%)
MU   50.07 (+0.18%)
AMD   56.07 (-2.10%)
T   29.88 (+1.15%)
F   5.98 (+2.22%)
GILD   76.14 (+1.91%)
DIS   119.04 (+1.90%)
BAC   23.37 (+2.64%)
NFLX   541.41 (+6.63%)
BA   176.35 (+1.77%)
AAPL   381.14 (-0.42%)
MSFT   212.65 (-0.78%)
FB   241.90 (-1.06%)
GOOGL   1,519.26 (+0.04%)
AMZN   3,179.87 (-0.09%)
NVDA   420.19 (-0.04%)
CGC   16.86 (+5.24%)
MU   50.07 (+0.18%)
AMD   56.07 (-2.10%)
T   29.88 (+1.15%)
F   5.98 (+2.22%)
GILD   76.14 (+1.91%)
DIS   119.04 (+1.90%)
BAC   23.37 (+2.64%)
NFLX   541.41 (+6.63%)
BA   176.35 (+1.77%)
Log in

NASDAQ:ICPTIntercept Pharmaceuticals Stock Price, Forecast & News

$45.62
+1.76 (+4.01 %)
(As of 07/10/2020 12:45 PM ET)
Add
Compare
Today's Range
$43.08
Now: $45.62
$46.24
50-Day Range
$44.05
MA: $71.72
$92.04
52-Week Range
$42.66
Now: $45.62
$125.00
Volume18,927 shs
Average Volume1.42 million shs
Market Capitalization$1.50 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.78
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.
Read More
Intercept Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.1Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.77 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ICPT
CUSIP45845P10
Phone646-747-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$252 million
Book Value$1.57 per share

Profitability

Net Income$-344,680,000.00
Net Margins-127.53%

Miscellaneous

Employees483
Market Cap$1.50 billion
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive ICPT News and Ratings via Email

Sign-up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter.

Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions

How has Intercept Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Intercept Pharmaceuticals' stock was trading at $77.60 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ICPT shares have decreased by 41.0% and is now trading at $45.81. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Intercept Pharmaceuticals?

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 16 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Intercept Pharmaceuticals.

When is Intercept Pharmaceuticals' next earnings date?

Intercept Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Intercept Pharmaceuticals.

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) posted its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported ($2.86) EPS for the quarter, topping the consensus estimate of ($2.94) by $0.08. The biopharmaceutical company had revenue of $72.60 million for the quarter, compared to the consensus estimate of $69.67 million. Intercept Pharmaceuticals had a negative net margin of 127.53% and a negative return on equity of 430.51%. The company's revenue was up 39.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($3.03) earnings per share. View Intercept Pharmaceuticals' earnings history.

What price target have analysts set for ICPT?

22 brokerages have issued 12-month target prices for Intercept Pharmaceuticals' stock. Their forecasts range from $46.00 to $140.00. On average, they expect Intercept Pharmaceuticals' share price to reach $74.64 in the next twelve months. This suggests a possible upside of 62.9% from the stock's current price. View analysts' price targets for Intercept Pharmaceuticals.

What are Wall Street analysts saying about Intercept Pharmaceuticals stock?

Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Intercept’s lead drug Ocaliva’s performance has been strong in the year so far. Management’s efforts to increase awareness about the label update of the drug in 2018 and expand sales force across the United States, thereafter, are yielding results. Solid growth in patient enrollment is likely to drive the company’s performance. Meanwhile, Intercept is working to expand the drug’s label in the promising NASH space. While the failure of Gilead’s late-stage study on selonsertib in patients suffering from compensated cirrhosis due to NASH puts Intercept ahead in the race, additional results from the REGENERATE study in NASH were mixed and did not impress investors. Nevertheless, a potential approval in this indication will significantly boost growth. However, shares have underperformed the industry in the year so far." (10/14/2019)
  • 2. Stifel Nicolaus analysts commented, "We are reiterating our Hold rating on ICPT after the company reported a slight 2Q19 beat on Ocaliva revenues, which appear to have been aided by a benefit in channel inventories. With that said, our thesis remains unchanged and we think there are too many unknown variables in terms of OCA’s potential adcom/approval and launch in NASH for us to be comfortable recommending the stock here. Management remains on track to file its NDA for OCA in NASH by the end of this quarter followed by its MAA filing in the EU in 4Q19. We think investor focus remains on the potential for OCA in NASH and in particular: whether or not ICPT’s filing of a NDA for OCA in NASH (rather than a sNDA) can lead to bi- furcated/indication based pricing, potential payer/reimbursement dynamics in the NASH category and the use of non-invasive biomarkers vs. biopsy for diagnosis." (8/12/2019)

Has Intercept Pharmaceuticals been receiving favorable news coverage?

News coverage about ICPT stock has been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Intercept Pharmaceuticals earned a news impact score of 1.2 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Intercept Pharmaceuticals.

Are investors shorting Intercept Pharmaceuticals?

Intercept Pharmaceuticals saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 5,790,000 shares, an increase of 5.7% from the May 31st total of 5,480,000 shares. Based on an average daily trading volume, of 690,200 shares, the days-to-cover ratio is currently 8.4 days. Approximately 22.2% of the company's shares are sold short. View Intercept Pharmaceuticals' Current Options Chain.

Who are some of Intercept Pharmaceuticals' key competitors?

What other stocks do shareholders of Intercept Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), Netflix (NFLX), Alibaba Group (BABA), NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Micron Technology (MU), Regeneron Pharmaceuticals (REGN) and Biogen (BIIB).

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the following people:
  • Dr. Mark Pruzanski, Founder, CEO, Pres & Director (Age 51)
  • Mr. Sandip S. Kapadia, CFO, Treasurer & Principal Accounting Officer (Age 49)
  • Mr. Jerome B. Durso, Chief Operating Officer (Age 51)
  • Mr. Ryan T. Sullivan, Gen. Counsel & Sec. (Age 43)
  • Dr. Gail Cawkwell, Sr. VP of Medical Affairs, Safety & Pharmacovigilance (Age 57)

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $45.81.

How big of a company is Intercept Pharmaceuticals?

Intercept Pharmaceuticals has a market capitalization of $1.51 billion and generates $252 million in revenue each year. The biopharmaceutical company earns $-344,680,000.00 in net income (profit) each year or ($10.89) on an earnings per share basis. Intercept Pharmaceuticals employs 483 workers across the globe.

What is Intercept Pharmaceuticals' official website?

The official website for Intercept Pharmaceuticals is www.interceptpharma.com.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.